PMID- 35348849
OWN - NLM
STAT- MEDLINE
DCOM- 20220520
LR  - 20220629
IS  - 1432-2013 (Electronic)
IS  - 0031-6768 (Linking)
VI  - 474
IP  - 6
DP  - 2022 Jun
TI  - Lipid metabolic reprogramming by hypoxia-inducible factor-1 in the hypoxic tumour 
      microenvironment.
PG  - 591-601
LID - 10.1007/s00424-022-02683-x [doi]
AB  - Cancer cells rewire metabolic processes to adapt to the nutrient- and 
      oxygen-deprived tumour microenvironment, thereby promoting their proliferation 
      and metastasis. Previous research has shown that modifying glucose metabolism, 
      the Warburg effect, makes glycolytic cancer cells more invasive and aggressive. 
      Lipid metabolism has also been receiving attention because lipids function as 
      energy sources and signalling molecules. Because obesity is a risk factor for 
      various cancer types, targeting lipid metabolism may be a promising cancer 
      therapy. Here, we review the lipid metabolic reprogramming in cancer cells 
      mediated by hypoxia-inducible factor-1 (HIF-1). HIF-1 is the master transcription 
      factor for tumour growth and metastasis by transactivating genes related to 
      proliferation, survival, angiogenesis, invasion, and metabolism. The glucose 
      metabolic shift (the Warburg effect) is mediated by HIF-1. Recent research on 
      HIF-1-related lipid metabolic reprogramming in cancer has confirmed that HIF-1 
      also modifies lipid accumulation, beta-oxidation, and lipolysis in cancer, 
      triggering its progression. Therefore, targeting lipid metabolic alterations by 
      HIF-1 has therapeutic potential for cancer. We summarize the role of the lipid 
      metabolic shift mediated by HIF-1 in cancer and its putative applications for 
      cancer therapy.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Seo, Jieun
AU  - Seo J
AD  - Department of Biomedical Sciences, Seoul National University College of Medicine, 
      Seoul, 03080, South Korea.
AD  - Department of Physiology, Seoul National University College of Medicine, Seoul, 
      03080, South Korea.
AD  - Faculty of Engineering, Yokohama National University, Yokohama, 240-8501, Japan.
AD  - Kanagawa Institute of Industrial Science and Technology, Kawasaki, 213-0012, 
      Japan.
FAU - Yun, Jeong-Eun
AU  - Yun JE
AD  - Department of Biomedical Sciences, Seoul National University College of Medicine, 
      Seoul, 03080, South Korea.
AD  - Department of Physiology, Seoul National University College of Medicine, Seoul, 
      03080, South Korea.
FAU - Kim, Sung Joon
AU  - Kim SJ
AD  - Department of Biomedical Sciences, Seoul National University College of Medicine, 
      Seoul, 03080, South Korea.
AD  - Department of Physiology, Seoul National University College of Medicine, Seoul, 
      03080, South Korea.
AD  - Ischemic/Hypoxic Disease Institute, Seoul National University College of 
      Medicine, Seoul, 03080, South Korea.
FAU - Chun, Yang-Sook
AU  - Chun YS
AUID- ORCID: 0000-0002-1261-9498
AD  - Department of Biomedical Sciences, Seoul National University College of Medicine, 
      Seoul, 03080, South Korea. chunys@snu.ac.kr.
AD  - Department of Physiology, Seoul National University College of Medicine, Seoul, 
      03080, South Korea. chunys@snu.ac.kr.
AD  - Ischemic/Hypoxic Disease Institute, Seoul National University College of 
      Medicine, Seoul, 03080, South Korea. chunys@snu.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220328
PL  - Germany
TA  - Pflugers Arch
JT  - Pflugers Archiv : European journal of physiology
JID - 0154720
RN  - 0 (Hypoxia-Inducible Factor 1)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (Lipids)
SB  - IM
MH  - Glycolysis
MH  - Humans
MH  - Hypoxia
MH  - Hypoxia-Inducible Factor 1/metabolism
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/metabolism
MH  - Lipids
MH  - *Neoplasms/metabolism
MH  - *Tumor Microenvironment
OTO - NOTNLM
OT  - Cancer therapy
OT  - Hypoxia-inducible factor-1
OT  - Lipid metabolism
OT  - Tumour microenvironment
EDAT- 2022/03/30 06:00
MHDA- 2022/05/21 06:00
CRDT- 2022/03/29 12:21
PHST- 2022/01/14 00:00 [received]
PHST- 2022/03/12 00:00 [accepted]
PHST- 2022/03/10 00:00 [revised]
PHST- 2022/03/30 06:00 [pubmed]
PHST- 2022/05/21 06:00 [medline]
PHST- 2022/03/29 12:21 [entrez]
AID - 10.1007/s00424-022-02683-x [pii]
AID - 10.1007/s00424-022-02683-x [doi]
PST - ppublish
SO  - Pflugers Arch. 2022 Jun;474(6):591-601. doi: 10.1007/s00424-022-02683-x. Epub 
      2022 Mar 28.